Publications by authors named "Marc B Schwartz"
Background & Aims: Investigating the tissue-associated microbiota after surgically induced remission may help to understand the mechanisms initiating intestinal inflammation in Crohn's disease.
Methods: Patients with Crohn's disease undergoing ileocolic resection were prospectively recruited in 6 academic centers. Biopsy samples from the neoterminal ileum, colon, and rectosigmoid were obtained from colonoscopies performed after surgery.
Background: We studied humoral responses after coronavirus disease 2019 (COVID-19) vaccination across varying causes of immunodeficiency.
Methods: Prospective study of fully vaccinated immunocompromised adults (solid organ transplant [SOT], hematologic malignancy, solid cancers, autoimmune conditions, human immunodeficiency virus [HIV]) versus nonimmunocompromised healthcare workers (HCWs). The primary outcome was the proportion with a reactive test (seropositive) for immunoglobulin G to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain.
Article Synopsis
- - Serrated epithelial change (SEC) occurs in patients with long-term inflammatory bowel disease (IBD), showing irregular crypt structures and a high number of goblet cells, and is linked to an increased risk of colorectal cancer.
- - A study analyzed genetic mutations in SEC, finding that TP53 mutations were common and linked to various stages of dysplasia and adenocarcinoma, while mutations in KRAS/BRAF were more prevalent in control serrated lesions.
- - The relationship between SEC and IBD-related cancer is still uncertain, and the research used targeted next-generation sequencing to investigate genetic changes in SEC and associated lesions in patients with IBD.
Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti-PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 in patients with PD-1-refractory melanoma.
View Article and Find Full Text PDFBackground And Aims: The U.S. population is aging and the burden of geriatric inflammatory bowel disease (IBD) patients has increased.
View Article and Find Full Text PDFBackground: Crohn's disease (CD) patients may be at increased risk for the development of Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL), either through exposure to immunosuppressive medications or due to their underlying chronic inflammatory illness. There are limited data regarding the natural history of CD following treatment of lymphoma. We present a series of CD patients who were treated for lymphoma and describe the natural history of their CD following lymphoma treatment.
View Article and Find Full Text PDF